COVAX-19
Sign in to saveAlso known as SpikoGen
COVAX-19 (or SpikoGen) is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company with operations in West Asia. It is under clinical trial in collaboration with the Iranian company CinnaGen.
~2 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Pharmacology
- History
- Clinical trials
- Authorisations
- See also
- References
COVAX-19 (or SpikoGen) is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company with operations in West Asia. It is under clinical trial in collaboration with the Iranian company CinnaGen.
== Medical uses == It requires two doses 21 days apart given by intramuscular injection.
Excerpted from Wikipedia’s “COVAX-19” article, available under the CC BY-SA 4.0 licence.